 |
[(S)-1-(L-valyl)-N_((S)-1-phenyl-2-(pyridin-2-yl)ethyl)pyrrolidine-2-carboxamide fumarate] |
|---|---|
| Trade Name | |
| Orphan Indication | Rett syndrome |
| USA Market Approval | USA |
| USA Designation Date | 2017-06-22 00:00:00 |
| Sponsor | Biohaven Pharmaceutics, Inc.;234 Church Street, Suite 304;New Haven, Connecticut, 06510 |
